Loading…

Can Oxytocin Enhance Social Affiliation in Schizophrenia?

Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several...

Full description

Saved in:
Bibliographic Details
Published in:Current behavioral neuroscience reports 2016-06, Vol.3 (2), p.131-143
Main Authors: Bhat, Ishrat, Buckner, Alex S., Ara, Anjum
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443
cites cdi_FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443
container_end_page 143
container_issue 2
container_start_page 131
container_title Current behavioral neuroscience reports
container_volume 3
creator Bhat, Ishrat
Buckner, Alex S.
Ara, Anjum
description Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several cognitive domains, including social cognition, are impaired in schizophrenia. Social cognition in schizophrenia is a rapidly emerging and major focus of schizophrenia research since deficits in various domains of social cognition lead to poorer outcomes and functioning. Although antipsychotic medications are effective in treating the positive and to some extent negative symptoms of schizophrenia, no pharmacological agents currently exist that are approved for treatment of impairment in social cognition associated with schizophrenia. Several studies have shown that oxytocin, a neurohormone, improves social affiliations in schizophrenia. Meta-analyses of such studies have demonstrated beneficial effect of oxytocin in the treatment of social cognitive impairments in schizophrenia in addition to having some adjunctive value in treating positive and negative symptoms. The role of oxytocin as an adjunct in the treatment of schizophrenia is based on the premise that oxytocin may have some role in the pathophysiology of schizophrenia in conjunction with several neurotransmitters. This review focuses on bringing the reader up-to-date on the subject with the main focus being on the latest research findings.
doi_str_mv 10.1007/s40473-016-0080-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2804059682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2804059682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMoWGp_gLcFz9HJ12ZzklLqBxR6qJ5DmiY2Zc2uSQvWX2_KCnrxNDPM-868PAhdE7glAPIuc-CSYSA1BmgAyzM0okTVmCqpzv_0l2iS8w4ACOFARDNCamZitfw87jsbYjWPWxOtq1ZlMm019T60wexDF6uyXdlt-Or6bXIxmPsrdOFNm93kp47R68P8ZfaEF8vH59l0gS1lRGIviVfGC7YuIYmiyjjGheTEiVoZZYWTXK0bVm8EGOtoLcwGmFQlsvKCczZGN8PdPnUfB5f3etcdUiwvNW2Ag1B1Q4uKDCqbupyT87pP4d2koyagT5D0AEkXSPoEScvioYMnF218c-n38v-mb-dZZuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2804059682</pqid></control><display><type>article</type><title>Can Oxytocin Enhance Social Affiliation in Schizophrenia?</title><source>Springer Nature</source><creator>Bhat, Ishrat ; Buckner, Alex S. ; Ara, Anjum</creator><creatorcontrib>Bhat, Ishrat ; Buckner, Alex S. ; Ara, Anjum</creatorcontrib><description>Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several cognitive domains, including social cognition, are impaired in schizophrenia. Social cognition in schizophrenia is a rapidly emerging and major focus of schizophrenia research since deficits in various domains of social cognition lead to poorer outcomes and functioning. Although antipsychotic medications are effective in treating the positive and to some extent negative symptoms of schizophrenia, no pharmacological agents currently exist that are approved for treatment of impairment in social cognition associated with schizophrenia. Several studies have shown that oxytocin, a neurohormone, improves social affiliations in schizophrenia. Meta-analyses of such studies have demonstrated beneficial effect of oxytocin in the treatment of social cognitive impairments in schizophrenia in addition to having some adjunctive value in treating positive and negative symptoms. The role of oxytocin as an adjunct in the treatment of schizophrenia is based on the premise that oxytocin may have some role in the pathophysiology of schizophrenia in conjunction with several neurotransmitters. This review focuses on bringing the reader up-to-date on the subject with the main focus being on the latest research findings.</description><identifier>ISSN: 2196-2979</identifier><identifier>EISSN: 2196-2979</identifier><identifier>DOI: 10.1007/s40473-016-0080-7</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antipsychotics ; Behavioral Therapy ; Brain research ; Cognition &amp; reasoning ; Cognitive ability ; Dopamine ; Emotions ; Hormones ; Hypothalamus ; Hypotheses ; Medicine ; Medicine &amp; Public Health ; Neurology ; Neuropeptides ; Pediatrics ; Pituitary gland ; Psychiatry ; Psychosis (A Ahmed ; Psychotropic drugs ; Schizophrenia ; Section Editor ; Social interaction ; Social perception ; Topical Collection on Psychosis</subject><ispartof>Current behavioral neuroscience reports, 2016-06, Vol.3 (2), p.131-143</ispartof><rights>Springer International Publishing AG 2016</rights><rights>Springer International Publishing AG 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443</citedby><cites>FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Bhat, Ishrat</creatorcontrib><creatorcontrib>Buckner, Alex S.</creatorcontrib><creatorcontrib>Ara, Anjum</creatorcontrib><title>Can Oxytocin Enhance Social Affiliation in Schizophrenia?</title><title>Current behavioral neuroscience reports</title><addtitle>Curr Behav Neurosci Rep</addtitle><description>Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several cognitive domains, including social cognition, are impaired in schizophrenia. Social cognition in schizophrenia is a rapidly emerging and major focus of schizophrenia research since deficits in various domains of social cognition lead to poorer outcomes and functioning. Although antipsychotic medications are effective in treating the positive and to some extent negative symptoms of schizophrenia, no pharmacological agents currently exist that are approved for treatment of impairment in social cognition associated with schizophrenia. Several studies have shown that oxytocin, a neurohormone, improves social affiliations in schizophrenia. Meta-analyses of such studies have demonstrated beneficial effect of oxytocin in the treatment of social cognitive impairments in schizophrenia in addition to having some adjunctive value in treating positive and negative symptoms. The role of oxytocin as an adjunct in the treatment of schizophrenia is based on the premise that oxytocin may have some role in the pathophysiology of schizophrenia in conjunction with several neurotransmitters. This review focuses on bringing the reader up-to-date on the subject with the main focus being on the latest research findings.</description><subject>Antipsychotics</subject><subject>Behavioral Therapy</subject><subject>Brain research</subject><subject>Cognition &amp; reasoning</subject><subject>Cognitive ability</subject><subject>Dopamine</subject><subject>Emotions</subject><subject>Hormones</subject><subject>Hypothalamus</subject><subject>Hypotheses</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neurology</subject><subject>Neuropeptides</subject><subject>Pediatrics</subject><subject>Pituitary gland</subject><subject>Psychiatry</subject><subject>Psychosis (A Ahmed</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>Section Editor</subject><subject>Social interaction</subject><subject>Social perception</subject><subject>Topical Collection on Psychosis</subject><issn>2196-2979</issn><issn>2196-2979</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMoWGp_gLcFz9HJ12ZzklLqBxR6qJ5DmiY2Zc2uSQvWX2_KCnrxNDPM-868PAhdE7glAPIuc-CSYSA1BmgAyzM0okTVmCqpzv_0l2iS8w4ACOFARDNCamZitfw87jsbYjWPWxOtq1ZlMm019T60wexDF6uyXdlt-Or6bXIxmPsrdOFNm93kp47R68P8ZfaEF8vH59l0gS1lRGIviVfGC7YuIYmiyjjGheTEiVoZZYWTXK0bVm8EGOtoLcwGmFQlsvKCczZGN8PdPnUfB5f3etcdUiwvNW2Ag1B1Q4uKDCqbupyT87pP4d2koyagT5D0AEkXSPoEScvioYMnF218c-n38v-mb-dZZuA</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Bhat, Ishrat</creator><creator>Buckner, Alex S.</creator><creator>Ara, Anjum</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20160601</creationdate><title>Can Oxytocin Enhance Social Affiliation in Schizophrenia?</title><author>Bhat, Ishrat ; Buckner, Alex S. ; Ara, Anjum</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antipsychotics</topic><topic>Behavioral Therapy</topic><topic>Brain research</topic><topic>Cognition &amp; reasoning</topic><topic>Cognitive ability</topic><topic>Dopamine</topic><topic>Emotions</topic><topic>Hormones</topic><topic>Hypothalamus</topic><topic>Hypotheses</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neurology</topic><topic>Neuropeptides</topic><topic>Pediatrics</topic><topic>Pituitary gland</topic><topic>Psychiatry</topic><topic>Psychosis (A Ahmed</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>Section Editor</topic><topic>Social interaction</topic><topic>Social perception</topic><topic>Topical Collection on Psychosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhat, Ishrat</creatorcontrib><creatorcontrib>Buckner, Alex S.</creatorcontrib><creatorcontrib>Ara, Anjum</creatorcontrib><collection>CrossRef</collection><jtitle>Current behavioral neuroscience reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhat, Ishrat</au><au>Buckner, Alex S.</au><au>Ara, Anjum</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can Oxytocin Enhance Social Affiliation in Schizophrenia?</atitle><jtitle>Current behavioral neuroscience reports</jtitle><stitle>Curr Behav Neurosci Rep</stitle><date>2016-06-01</date><risdate>2016</risdate><volume>3</volume><issue>2</issue><spage>131</spage><epage>143</epage><pages>131-143</pages><issn>2196-2979</issn><eissn>2196-2979</eissn><abstract>Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several cognitive domains, including social cognition, are impaired in schizophrenia. Social cognition in schizophrenia is a rapidly emerging and major focus of schizophrenia research since deficits in various domains of social cognition lead to poorer outcomes and functioning. Although antipsychotic medications are effective in treating the positive and to some extent negative symptoms of schizophrenia, no pharmacological agents currently exist that are approved for treatment of impairment in social cognition associated with schizophrenia. Several studies have shown that oxytocin, a neurohormone, improves social affiliations in schizophrenia. Meta-analyses of such studies have demonstrated beneficial effect of oxytocin in the treatment of social cognitive impairments in schizophrenia in addition to having some adjunctive value in treating positive and negative symptoms. The role of oxytocin as an adjunct in the treatment of schizophrenia is based on the premise that oxytocin may have some role in the pathophysiology of schizophrenia in conjunction with several neurotransmitters. This review focuses on bringing the reader up-to-date on the subject with the main focus being on the latest research findings.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s40473-016-0080-7</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2196-2979
ispartof Current behavioral neuroscience reports, 2016-06, Vol.3 (2), p.131-143
issn 2196-2979
2196-2979
language eng
recordid cdi_proquest_journals_2804059682
source Springer Nature
subjects Antipsychotics
Behavioral Therapy
Brain research
Cognition & reasoning
Cognitive ability
Dopamine
Emotions
Hormones
Hypothalamus
Hypotheses
Medicine
Medicine & Public Health
Neurology
Neuropeptides
Pediatrics
Pituitary gland
Psychiatry
Psychosis (A Ahmed
Psychotropic drugs
Schizophrenia
Section Editor
Social interaction
Social perception
Topical Collection on Psychosis
title Can Oxytocin Enhance Social Affiliation in Schizophrenia?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20Oxytocin%20Enhance%20Social%20Affiliation%20in%20Schizophrenia?&rft.jtitle=Current%20behavioral%20neuroscience%20reports&rft.au=Bhat,%20Ishrat&rft.date=2016-06-01&rft.volume=3&rft.issue=2&rft.spage=131&rft.epage=143&rft.pages=131-143&rft.issn=2196-2979&rft.eissn=2196-2979&rft_id=info:doi/10.1007/s40473-016-0080-7&rft_dat=%3Cproquest_cross%3E2804059682%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2317-f71f9af53b4041929ae345741e569a9c5e749b836d50ace265ad03791969f5443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2804059682&rft_id=info:pmid/&rfr_iscdi=true